复星医药(02196.HK)发布公告，2025年10月28日，本公司控股子公司复星医药产业与其他11方投资人共 同签订《合伙协议》，拟作为LP现金出资人民币1亿元参与出资设立目标基金。目标基金将主要投资于 化学创新药、生物药(含疫苗)、高端医疗器械(含IVD)、中药滋补品类、合成生物学等战略新兴细分领 域的企业。 复星医药港股市值127.99亿港元，在生物制品Ⅱ行业中排名第13。主要指标见下表： | 指标 | 复星医药 | 生物制品ll 行业平均 | 行业排名 | | --- | --- | --- | --- | | ROE | 6.89% | 10.46% | 15 50 | | 港股流通市值 | 127.99 乙 | 211.96 乙 | 13 50 | | 营业收入 | 399.52亿 | 25.4亿 | 1 20 | | 净利率 | 10.81% | -381.46% | 14 50 | | 毛利率 | 47.89% | 59.38% | 32 50 | | 员债率 | 49.26% | 74.41% | 33 50 | 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备3101043457 ...

格隆汇10月28日丨复星医药(02196.HK)公告，2025年10月28日，公司控股子公司复星医药产业与其他11 方投资人共同签订《合伙协议》，拟作为LP现金出资人民币10,000万元参与出资设立目标基金。目标基 金将主要投资于化学创新药、生物药(含疫苗)、高端医疗器械(含IVD)、中药滋补品类、合成生物学等 战略新兴细分领域的企业。 来源：格隆汇APP ...

格隆汇10月28日丨复星医药(02196.HK)公告，2025年10月28日，公司控股子公司复星医药产业与其他11 方投资人共同签订《合伙协议》，拟作为LP现金出资人民币10,000万元参与出资设立目标基金。目标基 金将主要投资于化学创新药、生物药(含疫苗)、高端医疗器械(含IVD)、中药滋补品类、合成生物学等 战略新兴细分领域的企业。 ...

本次投资旨在充分发挥本集团与华润医药各自在大健康领域优势，并结合成都当地产业政策和区位优 势，积极拓展本集团在创新药、生物药、高端医疗器械、合成生物以及其他战略性新兴领域布局的渠道 并获取投资回报。 目标基金设立后，将成为本公司的联营企业。 复星医药（600196）(02196)发布公告，2025年10月28日，本公司控股子公司复星医药产业与其他11方 投资人共同签订《合伙协议》，拟作为LP现金出资人民币1亿元参与出资设立目标基金。目标基金将主 要投资于化学创新药、生物药(含疫苗)、高端医疗器械(含IVD)、中药滋补品类、合成生物学等战略新 兴细分领域的企业。 ...

复星医药（600196）公告要点解读 投资事项：控股子公司复星医药产业拟作为LP，出资1亿元人民币，与其他11方共同设立私募股权投资 基金，目标基金总募集规模10亿元，主要投资于化学创新药、生物药（含疫苗）、高端医疗器械（含 IVD）、中药滋补品、合成生物学等领域。 出资结构：复星医药产业认缴10%，成都重产二期基金、成都高新策源基金各19.7%，成都交子产业基 金14.85%，华润方投资人合计21.75%，其余为其他投资人。 基金管理：管理人为华润资本，基金存续期7年（含3年投资期、4年退出期），可延长1年。 决策机制：投委会7人，复星医药产业有权提名1人，重大事项需2/3以上委员同意。 风险提示：基金尚处筹备阶段，实际募集及出资存在不确定性，投资周期长，无保本及最低收益承诺。 ...

为促进科技与产业有效衔接，活动还发布了7家重点企业的技术需求以及11项融资需求，总资金需 求规模达数亿元，涉及新药研发、生产线扩建、临床申报等多个环节。两家企业代表在现场路演中分享 了企业在技术创新与产业升级方面的迫切诉求。同时，两家金融投资机构介绍了针对生物医药企业的政 策性金融工具与市场化投资方案，推动科技成果从实验室走向产业化。现场交流活跃，初步达成合作意 向10项，为广西生物医药产业高质量发展注入新动能。（梁菁惠） 活动现场集中展示了34项技术成果，覆盖中药新药、院内制剂转化、医疗器械、化学创新药等多个 前沿领域。来自广西中医药大学、广西医科大学第一附属医院、玉林市中西医结合骨科医院等单位的8 个技术成果团队进行了现场路演，充分展现了广西在药品与医疗器械创新方面的扎实基础与科研实力。 近日，以"产学研用金协同 共筑产业新生态"为主题的广西生物医药产业"产学研用金"对接活动在 广西中医药大学举办。此次活动是广西首次聚焦生物医药领域创新成果与生产企业精准对接的专项活 动，旨在推动产业链、创新链、资金链与人才链深度融合，将本地资源优势切实转化为产业发展优势。 ...

Core Viewpoint - The establishment of a 1 billion yuan investment fund by companies under China Resources, in collaboration with Shanghai Fosun Pharmaceutical and Chengdu state-owned enterprises, aims to focus on the pharmaceutical and health sectors, particularly in innovative drug development and strategic emerging industries [2][4]. Group 1: Fund Structure and Partners - The fund, named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund, has a total capital of 100 million yuan, with various partners contributing different amounts [3]. - The general partner (GP) is China Resources Pharmaceutical (Chengdu) Enterprise Management Partnership (Limited Partnership), while limited partners (LPs) include several pharmaceutical companies and investment funds [2][3]. - The fund's lifespan is set for 7 years, with a 3-year investment period and a 4-year exit period, extendable by 1 year upon partner approval [3]. Group 2: Investment Focus - The fund will concentrate on the pharmaceutical health sector and strategic emerging industries, targeting areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices, and traditional Chinese medicine [4]. - The involvement of the Chengdu Bio-City Jingchuang Equity Investment Fund indicates a strong potential for project implementation within the Chengdu Tianfu International Bio-City [4]. Group 3: Historical Context - An earlier fund, the China Resources Pharmaceutical (Shantou) Industry Investment Fund, was established 8 years ago but did not perform as expected, failing to reach its initial target of 2.5 billion yuan [4][6]. - The Shantou fund entered a liquidation phase in December 2024, having not achieved the anticipated scale, which affected the contributions of its partners [5][6].

Group 1 - China Resources Pharmaceutical (03320.HK) announced the establishment of a joint venture fund named China Resources Pharmaceutical (Chengdu) Innovation Investment Fund Partnership (Limited Partnership) with a proposed scale of RMB 1 billion and a total duration of seven years [1] - The group's proposed capital contribution will be approximately RMB 245 million, accounting for about 24.5% of the total fund capital [1] - The fund is expected to primarily engage in equity investment, venture capital, and investment management activities, focusing on the pharmaceutical and health industry as well as strategic emerging sectors [1] Group 2 - The fund will target investments in areas such as chemical innovative drugs, biological drugs (including vaccines), high-end medical devices (including IVD), traditional Chinese medicine supplements, and synthetic biology, among other strategic emerging fields [1] - The company believes it can leverage the fund's professional investment team resources to effectively control risks associated with mergers and acquisitions and innovation projects, ensuring the quality of target companies and accelerating strategic mergers and acquisitions in the pharmaceutical industry [2] - This strategy aims to enhance the company's long-term sustainable development capabilities within the pharmaceutical sector [2]

Core Viewpoint - The State Administration for Market Regulation and the Ministry of Industry and Information Technology have issued the "Measurement Support Action Plan for the Development of New Quality Productive Forces (2025-2030)" focusing on key areas related to public health and biotechnology [1] Group 1: Key Areas of Focus - The plan emphasizes the importance of biotechnology, diagnostic equipment, and drug development in enhancing public health [1] - Specific directions include research on critical technologies for measurement and quality evaluation in pharmaceuticals, vaccines, advanced diagnostic technologies, wearable devices, precision medicine, and testing [1] Group 2: Research and Development Initiatives - Major initiatives will involve significant prevention and control measures, chemical innovative drugs, biopharmaceuticals, high-throughput gene sequencing, cell therapy, biological testing, in vitro diagnostic products, synthetic biology products, organoid products, and medical robots [1] - The plan aims to promote interdisciplinary integration in pharmacology, physiology, and synthetic biology to accelerate the application of related technologies in new drug development, disease treatment, and specialized medical food formulations [1]

Core Viewpoint - Hainan Haiyao has signed a strategic cooperation framework agreement with Aikang International Group to enhance collaboration in the health sector and promote the construction of Hainan Free Trade Port, aiming to expand market presence in both China and Malaysia [1][2]. Group 1: Strategic Cooperation - Hainan Haiyao will act as the exclusive agent for Aikang Group's health products in mainland China, responsible for promotion, sales, and after-sales service [1]. - Aikang Group will serve as the exclusive agent for Hainan Haiyao's traditional Chinese medicine products in Malaysia, facilitating their entry into the Malaysian market [1][2]. - Both parties will conduct market research and develop promotional strategies tailored to Malaysian consumer needs, enhancing brand recognition in Southeast Asia [1][2]. Group 2: Operational Framework - Annual cooperation summits will be held alternately in Hainan Free Trade Port and Malaysia to assess progress and plan future actions [2]. - A joint working group will be established to oversee the implementation of the cooperation, ensuring effective communication and problem resolution [2]. - The agreement lays a foundation for future formal cooperation, leveraging shared resources and expertise to enhance product offerings in the health sector [2]. Group 3: Company Background - Hainan Haiyao, established in 1965 and listed in 1994, is a leading pharmaceutical enterprise in Hainan Province, with a diverse product range including intermediates, active pharmaceutical ingredients, innovative chemical drugs, modern Chinese medicine, biological drugs, and high-end medical devices [3].